| mexiletine / Generic mfg. |
ChiCTR-TRC-14004180: Stratified-block Randomized, Double-blind, Positive and Placebo-controlled, Multicenter and Re-evaluation of post-marketing Traditional Chinese Medicine Clinical Trial for VPB Treated with MSN Capsule |
|
|
| Completed | 4 | 900 | | XSN Capsule: oral, 4 capsules each time, three times a day；Mexiletine hydrochloride simulation agent: oral, 2 tablets (50 mg/tablet) each time, 3 times a day; ;mexiletine hydrochloride: oral, 2 tablets (50 mg/tablet) each time, 3 times a day;XSN Capsule simulation agent: oral, 4 tablets each time, 3 times a day; ;XSN Capsule simulation agent: oral, 4 tablets each time, 3 times a day;Mexiletine hydrochloride simulation agent, oral, 2 tablets (50 mg/tablet), 3 times a day | BeijingChao-YangHospital; Level of the institution：, Shanxi Momentum Pharmaceutcal Company | ventricular premature beat | | | | |
| Ongoing | 3 | 32 | Europe | Capsule, hard, Capsule, Namuscla, Lamotrigin â€Nordic Prime" 25 mg, Lamotrigin â€Nordic Prime" 50 mg, Lamotrigin â€Nordic Prime" 100 mg | Rigshospitalet, department of Neurology, Region Hovedstadens Forskningsfond til Sundhedsforskning | Myotonia Congenita (Becker and Thomsen type), Paramyotonia Congenita, and Hyperkalemic periodic paralysis, Non-dystofic myotonia, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
| Recruiting | 3 | 60 | Europe | Mexiletine, Lamotrigine 25Mg Oral Tablet, Extended Release | University College, London | Non-Dystrophic Myotonia | 08/23 | 04/24 | | |
| Recruiting | 3 | 14 | Europe | Mexiletine, Namuscla ™ | Lupin Ltd. | Myotonic Dystrophy | 06/24 | 08/24 | | |
MIND, NCT04700046: Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2 |
|
|
| Withdrawn | 3 | 158 | NA | Mexiletine 167 mg, Placebo | Lupin Ltd. | Myotonic Dystrophy Type 1 and Type 2 | 07/24 | 08/24 | | |
2014-002627-10: Pivotal study to evaluate the efficacy and safety of riluzole versus mexiletine in patients with non dystrophic myotonia mutated in SCN4A orCLCN1 genes. Studio clinico pilota per valutare l'efficacia e la sicurezza di riluzolo rispetto mexiletina in pazienti affetti da miotonia non distrofica mutati nei geniSCN4A o CLCN1. |
|
|
| Ongoing | 2 | 58 | Europe | RILUZOLO, Capsule, hard, RILUZOLO TEVA - 50 MG COMPRESSE RIVESTITE CON FILM 90 COMPRESSE IN BLISTER AL/PVC | FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA, MINISTERO DELLA SALUTE - FONDI 5 X 1000 | NDM patients with mutations in SCN4A or CLCN1 gene Miotonie non distrofiche con mutazione nei geni SCN4A o CLCN1, Patients with myotonic phenomenon Pazienti con fenomeno miotonico, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT05639257: Treatment of Myotonia - Lamotrigine Versus Namuscla |
|
|
| Recruiting | N/A | 32 | Europe | Lamotrigine, Namuscla, mexiletine | Grete Andersen, MD, GCP-Copenhagen, Region Capital Denmark, Danish Region, Lupin Atlantis Holdings S.A., ZiteLab | Non-Dystrophic Myotonia | 04/24 | 04/24 | | |
NCT05619120: The Effect of Late Na Current Blocker Mexiletine on Giant T-wave Electrical Alternans(STOP-TWA) |
|
|
| Recruiting | N/A | 50 | RoW | Mexiletine, Conventional therapy | First Affiliated Hospital Xi'an Jiaotong University | Giant T-wave Electrical Alternans | 06/25 | 12/25 | | |
NCT04616807: An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders |
|
|
| Active, not recruiting | N/A | 53 | Europe | Mexiletine, Namuscla ™ | Lupin Ltd. | Myotonic Dystrophy | 12/25 | 01/26 | | |
| Active, not recruiting | N/A | 14 | Europe | Mexiletine, Namuscla ™ | Lupin Ltd. | Myotonic Disorders | 01/26 | 03/26 | | |
